Corvex (MOVE) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We are an early-stage technology company with a limited history of generating revenue, have a history of operating losses, and we may never achieve or maintain profitability
2. 02We may be unable to continue as a going concern if we do not successfully raise additional capital on favorable terms, or at all, or if we fail to generate sufficient revenue from operations
3. 03Our efforts may never demonstrate the feasibility of our proposed CGM and blood pressure monitoring solution
4. 04We face competition from other technology companies and our operating results will suffer if we fail to compete effectively
5. 05If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
6. 06We are subject to risks associated with our utilization of consultants
7. 07We will need to grow the size of our organization, and we may experience difficulties in managing this growth
8. 08We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions
9. 09Our business is affected by macroeconomic conditions
10. 10Our business and operations are subject to risks related to climate change
11. 11The sizes of the markets for our current and future products have not been established with precision and may be smaller than we estimate
12. 12Our business could be negatively impacted by corporate social responsibility and sustainability matters

Risks Related to Product Development, Manufacturing and Commercialization

1. 13We are highly dependent on the success of our initial products, the Evie Ring and the EvieMED Ring, and cannot give any assurance that they will be successfully commercialized
2. 14If we do not successfully manage the launch and marketing of new products or services, our financial results could be adversely affected
3. 15We depend on third parties to design, manufacture, market and distribute our products. If any third party fails to successfully design, manufacture, market or distribute any of our products, our business will be materially harmed
4. 16Our business and operations would suffer in the event of information technology system failures, including cyber-attacks
5. 17The use of artificial intelligence presents new risks and challenges to our business

Risks Related to Intellectual Property and Other Legal Matters

1. 18It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection
2. 19If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected
3. 20We may in the future be a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to develop our products
4. 21We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property
5. 22We could become subject to product liability claims, product recalls and warranty claims that could be expensive, divert management’s attention and harm our business
6. 23Increased use of social media could create or amplify the effects of negative publicity and adversely affect sales and operating results

Risks Related to Regulation

1. 24FDA clearance of the pulse oximetry feature of our EvieMED Ring does not ensure commercial success of the product
2. 25If any of these events were to occur, our business and financial condition would be harmed
3. 26If any OEMs contracted to manufacture our products fail to comply with FDA’s Quality System Regulations or other regulatory bodies’ equivalent regulations, manufacturing operations could be delayed or shut down and the development of our products could suffer
4. 27We expect our planned solution to be subject to certain Federal Communication Commission (“FCC”) regulations
5. 28Our current or future products may be subject to product recalls that could harm our reputation
6. 29Healthcare reform measures could hinder or prevent our commercial success
7. 30If we fail to comply with healthcare regulations with respect to our current or future products, we could face substantial penalties and our business, operations and financial condition could be adversely affected
8. 31Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to our reputation and have a material adverse effect on our business

Risks Related to Owning Our Securities and Our Financial Results

1. 32Our quarterly and annual results may fluctuate significantly, may not fully reflect the underlying performance of our business and may result in decreases in the price of our securities
2. 33Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
3. 34The issuance of additional stock in connection with financings, acquisitions, our equity incentive plan, upon exercise of outstanding warrants or otherwise will dilute our existing stockholders
4. 35Our stock price has fluctuated widely and is likely to continue to be volatile
5. 36Our failure to meet the continued listing requirements of Nasdaq could result in a de-listing of our common stock
6. 37Our Certificate of Incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
7. 38We have not paid dividends in the past and have no immediate plans to pay dividends
8. 39Concentration of ownership among our existing executive officers, directors and significant stockholders may prevent new investors from influencing significant corporate decisions
9. 40We are an “emerging growth company” under the JOBS Act and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors
10. 41We are incurring significant costs as a public company that reports to the SEC and our management is required to devote substantial time to meet compliance obligations
11. 42If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, the price of our common stock and trading volume could decline
12. 43Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable